List view / Grid view
Download your FREE ebook on assays, featuring articles from experts who write about developments in screening and the importance of performing comprehensive multiplex spatial and temporal profiling of drugs in pre-clinical research.
In this ebook are articles on the future potential for mRNA therapies and combatting new variants of the SARS-CoV-2.
A new Drug Target Review is now ready to download! This issue features articles which explore antibodies, vaccines and assays.
For International Women's Day, Drug Target Review’s Izzy Wood recently spoke to Lindsey Clarke about her experience as a woman in STEM.
Oestrogen receptors play a crucial role in breast cancer. By making them therapeutic targets, oestrogen can be regulated with the aim to prevent breast cancer.
In this article Drug Target Review's Izzy Wood highlights three of the latest findings using lab automation techniques and technologies that aid scientists.
In this exclusive article, Drug Target Review’s Izzy Wood highlights ground-breaking ovarian cancer research, after speaking with Dr Benjamin Neuditschko, from the Institute Krems Bioanalytics at IMC Krems.
Researchers found that ‘rational vaccinology’ increases potency by changing the structural location of antigens and adjuvants.
Technology is infamous for falling into a hype cycle, with its peaks and valleys of exaggerated expectations and disillusionment — AI-driven drug discovery is no exception. In this article, Aaron Daugherty, Vice President Discovery at Aria Pharmaceuticals, highlights how the industry can use AI to transform research.
Drug discovery trends in 2023 will change the way we conduct science and result in entirely new, more efficient, and effective research paradigms. Through increased public-private partnerships, multidisciplinary collaboration and patient engagement in the drug discovery process, we will see new vaccines and therapies getting to the public faster and…
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
Drug Target Review’s Izzy Wood spoke to Joseph Hernandez, CEO of Blue Water Vaccines, about developing transformational vaccines to address significant health challenges globally.
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
